News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
264,338 Results
Type
Article (13715)
Company Profile (101)
Press Release (250522)
Section
Business (88057)
Career Advice (473)
Deals (15344)
Drug Delivery (66)
Drug Development (36586)
Employer Resources (49)
FDA (6285)
Job Trends (6194)
News (150224)
Policy (14029)
Tag
Academia (438)
Alliances (23211)
Alzheimer's disease (376)
Approvals (6307)
Artificial intelligence (93)
Bankruptcy (146)
Best Places to Work (4371)
Breast cancer (70)
Cancer (520)
Cardiovascular disease (54)
Career advice (411)
Cell therapy (73)
Clinical research (30766)
Collaboration (283)
Compensation (116)
COVID-19 (754)
C-suite (97)
Data (521)
Diabetes (69)
Diagnostics (1311)
Drug discovery (49)
Drug pricing (61)
Earnings (31876)
Events (37240)
Executive appointments (322)
FDA (6614)
Funding (176)
Gene therapy (90)
GLP-1 (324)
Government (1280)
Healthcare (3557)
Infectious disease (783)
Inflammatory bowel disease (54)
Interviews (61)
IPO (5870)
Job creations (2050)
Job search strategy (377)
Layoffs (175)
Legal (3428)
Lung cancer (71)
Manufacturing (126)
Medical device (1281)
Medtech (1283)
Mergers & acquisitions (9621)
Metabolic disorders (219)
Neuroscience (524)
NextGen: Class of 2025 (1585)
Non-profit (602)
Northern California (623)
Obesity (124)
Opinion (116)
Patents (91)
People (28789)
Pharmaceutical (64)
Phase I (8006)
Phase II (13017)
Phase III (11678)
Pipeline (301)
Policy (53)
Postmarket research (1401)
Preclinical (3192)
Radiopharmaceuticals (118)
Rare diseases (147)
Real estate (2633)
Regulatory (10030)
Research institute (563)
Resumes & cover letters (56)
Southern California (620)
Startups (1633)
United States (6190)
Vaccines (135)
Weight loss (89)
Date
Today (46)
Last 7 days (285)
Last 30 days (1043)
Last 365 days (12368)
2025 (2062)
2024 (12513)
2023 (14265)
2022 (19565)
2021 (20069)
2020 (19038)
2019 (14892)
2018 (11723)
2017 (13896)
2016 (13132)
2015 (15477)
2014 (12425)
2013 (10596)
2012 (11404)
2011 (11931)
2010 (10896)
Location
Africa (313)
Asia (20016)
Australia (2595)
California (1491)
Canada (810)
China (194)
Colorado (61)
Connecticut (61)
Delaware (48)
Europe (39213)
Florida (263)
Illinois (165)
Indiana (120)
Japan (76)
Kansas (53)
Maryland (224)
Massachusetts (1268)
Minnesota (82)
New Jersey (636)
New York (421)
North Carolina (350)
Northern California (623)
Pennsylvania (373)
South America (500)
Southern California (620)
Texas (194)
Virginia (62)
Washington State (101)
264,338 Results for "portola pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
October 17, 2024
·
5 min read
Regulatory
Kezar’s Lupus Trial Paused After Four Patient Deaths
The clinical hold doesn’t cover its drug’s Investigational New Drug application for autoimmune hepatitis, for which the Phase IIa PORTOLA trial is ongoing.
October 7, 2024
·
2 min read
·
Tristan Manalac
Deals
Portola Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Sale Of Portola Pharmaceuticals, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) to Alexion Pharmaceuticals, Inc. for $18 per share in cash is fair to Portola shareholders.
May 5, 2020
·
1 min read
Business
Former Portola CEO Takes the Helm at T-Cell Cancer Therapy Company
Scott Garland, the former chief executive officer of Portola Pharmaceuticals, will become the next CEO of South San Francisco-based PACT Pharma.
March 5, 2021
·
3 min read
·
Alex Keown
Policy
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Portola Pharmaceuticals, Inc.
Rowley Law PLLC is investigating potential securities law violations by Portola Pharmaceuticals, Inc. and its board of directors concerning the proposed acquisition of the company by Alexion Pharmaceuticals, Inc. Stockholders will receive $18.00 for each share of Portola Pharmaceuticals stock that they hold.
May 5, 2020
·
1 min read
Biotech Bay
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences on March 2020
Portola Pharmaceuticals, Inc.® announced that the Company will participate in the following conferences in March.
February 24, 2020
·
1 min read
Policy
SHAREHOLDER ALERT: WeissLaw LLP Investigates Portola Pharmaceuticals, Inc.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Portola Pharmaceuticals, Inc. in connection with the proposed acquisition of the Company by Alexion Pharmaceuticals, Inc.
May 5, 2020
·
2 min read
Layoffs
Marinus Pharmaceuticals Lays Off 45% of Employees
The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.
November 14, 2024
·
1 min read
·
Angela Gabriel
Press Releases
Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales
February 25, 2025
·
9 min read
Deals
Alexion Completes Acquisition of Portola
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). The acquisition adds Factor Xa inhibitor reversal agent Andexxa ® [coagulation factor Xa (recombinant), in
July 2, 2020
·
8 min read
1 of 26,434
Next
